Follow-up of sperm concentration and motility in patients with lymphoma

R. Tal, A. Botchan, R. Hauser, L. Yogev, G. Paz, H. Yavetz

Research output: Contribution to journalArticlepeer-review

Abstract

Lymphomas are a group of diseases, prevalent at reproductive age. Fertility is notoriously reduced among lymphoma patients. This study evaluates pre- and post-treatment semen concentration and motility, and factors associated with semen quality deterioration. We followed-up 33 patients with non-Hodgkin's lymphoma or with Hodgkin's disease during the years 1987-1997 who were referred for semen cryopreservation. Pretreatment semen analysis, and hormonal profile were recorded at diagnosis and at least 1 year after completion of the treatment, and compared. Medical records for disease type, disease stage and treatment protocols were related to long-term sperm outcome. Hormonal concentrations were not predictive of post-treatment sperm concentration. In patients with localized disease, initial sperm concentration and motility tended to be preserved, compared with patients with widespread disease (P = 0.016). In Hodgkin's disease patients, treatment with the adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) protocol was superior to the mechloretamine, vincristine, procarbazine and prednisone with ABV protocol regarding germinal toxicity (P = 0.0008). The post-treatment sperm outcome was better in patients treated with local irradiation than in those who did not undergo irradiation (P = 0.0027). No predictive tools for post-treatment fertility were found and, therefore, every patient with a lymphoma should have his semen cryopreserved at diagnosis.

Original languageEnglish
Pages (from-to)1985-1988
Number of pages4
JournalHuman Reproduction
Volume15
Issue number9
DOIs
StatePublished - 2000
Externally publishedYes

Keywords

  • Fertility
  • Hodgkin's disease
  • Lymphoma
  • Non-Hodgkins' lymphoma
  • Semen

Fingerprint

Dive into the research topics of 'Follow-up of sperm concentration and motility in patients with lymphoma'. Together they form a unique fingerprint.

Cite this